← Product Code [KWD](/submissions/OR/subpart-d%E2%80%94prosthetic-devices/KWD) · K031859
# CAP GREAT TOE RESURFACING HEMI-ARTHROPLASTY IMPLANT (K031859)
_Arthrosurface, Inc. · KWD · Feb 18, 2004 · Orthopedic · SESE_
**Canonical URL:** https://fda.innolitics.com/submissions/OR/subpart-d%E2%80%94prosthetic-devices/KWD/K031859
## Device Facts
- **Applicant:** Arthrosurface, Inc.
- **Product Code:** [KWD](/submissions/OR/subpart-d%E2%80%94prosthetic-devices/KWD.md)
- **Decision Date:** Feb 18, 2004
- **Decision:** SESE
- **Submission Type:** Traditional
- **Regulation:** 21 CFR 888.3730
- **Device Class:** Class 2
- **Review Panel:** Orthopedic
- **Attributes:** Therapeutic
## Intended Use
Hemi arthroplasty implant for first metatarsophalangeal joint for use in the treatment of patients with degenerative and post-traumatic arthritis in the first metatarsal joint in the presence of good bone stock along with the following clinical conditions; hallux valgus or hallux limitus, hallux rigidus, and an unstable or painful metatarsal/phalangeal (MTP) joint. The device is a single use implant intended to be used with bone cement.
## Device Story
CAP™ Great Toe Resurfacing Hemi-arthroplasty is a 2-piece modular implant for first MTP joint arthroplasty. Components include a Ti-6Al-4V ELI taper post and a cobalt-chrome-molybdenum articular component with CP titanium coating. Surgeon uses provided instrumentation (drill guide, contact probe) to define a working axis, measure articular topography, and select an appropriately sized articular component. The device is implanted using bone cement. The system minimizes bone resection compared to traditional implants, aiming to restore physiological load distribution. Used in clinical settings by orthopedic surgeons to treat arthritis and joint instability/pain. Benefits include precise anatomical fit, joint surface resurfacing, and preservation of bone for potential future procedures.
## Clinical Evidence
Bench testing only. No clinical data provided. Mechanical testing included axial assembly/disassembly, rigidity characterization, cyclic fatigue, fretting/corrosion (ASTM F897), and torque resistance (ISO 7206-9). Surface coating performance referenced via Master Device File MAF-1085.
## Technological Characteristics
2-piece modular implant. Taper post: Ti-6Al-4V ELI (ASTM F136). Articular component: Cobalt-Chromium-Molybdenum (ASTM F799, ASTM F1537) with CP Titanium plasma spray coating. Fixation: Bone cement. Mechanical taper interlock. Instrumentation includes drill guide and contact probe for anatomical sizing.
## Regulatory Identification
A toe joint phalangeal (hemi-toe) polymer prosthesis is a device made of silicone elastomer intended to be implanted to replace the base of the proximal phalanx of the toe.
## Predicate Devices
- Implant, H.P. condylar, Dow Corning Wright ([K781870](/device/K781870.md))
- Swanson Titanium Great Toe Implant, Dow Corning Wright ([K864492](/device/K864492.md))
- K2 Hemi-Toe Implant System, Kinetikos Medical, Inc. ([K023770](/device/K023770.md))
- Futura Biomedical Metal Hemi Toe Implant, Futura Biomedical ([K971047](/device/K971047.md))
- Townley Great Toe Joint, Biopro, Inc. ([K911378](/device/K911378.md))
## Submission Summary (Full Text)
> This content was OCRed from public FDA records by [Innolitics](https://innolitics.com). If you use, quote, summarize, crawl, or train on this content, cite Innolitics at https://innolitics.com.
>
> Innolitics is a medical-device software consultancy. We help companies design, build, and clear FDA-regulated software and AI/ML devices, including [a 510(k)](https://innolitics.com/services/510ks/), [a De Novo](https://innolitics.com/services/regulatory/), [a SaMD](https://innolitics.com/services/end-to-end-samd/), [an AI/ML medical device](https://innolitics.com/services/medical-imaging-ai-development/), or [an FDA regulatory strategy](https://innolitics.com/services/regulatory/).
{0}------------------------------------------------
K031859 pg
510(k) Premarket Notification CAP™ Great Toe Resurfacing Hemi-arthroplasty Implant
# 510(K) SUMMARY OF SAFETY AND EFFECTIVENESS (21 CFR 807.92) [21 CFR 807.87(H)]
# CAP™ GREAT TOE RESURFACING HEMI-ARTHROPLASTY IMPLANT
In accordance with the Food and Drug Administration Rule to implement provisions of the Safe Medical Devices Act of 1990 and in conformance with 21 CFR 807.87(h), this information serves as a Summary of Safety and Effectiveness for the CAP™ Great Toe Resurfacing Hemi-arthroplasty implant.
| Submitted By: | STD Manufacturing, Inc.
1063 Turnpike Street
Stoughton, MA 02072
(781) 828-4400 |
|-------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Date: | May 30, 2003 |
| Contact Person: | Steven W. Ek, VP of Development |
| Proprietary Name: | CAP™ Great Toe Resurfacing Hemi-arthroplasty
implant |
| Common Name: | Toe joint, Phalangeal (hemi-toe) prosthesis |
| Classification Name: | Toe joint phalangeal (hemi-toe) prosthesis |
| Device Classification: | Class II |
| Review Panel: | Orthopedic |
| C.F.R. identification
reference: | 21 CFR § 888.3730 (2002) |
| Product Code: | KWD |
| Indications for Use: | Hemi arthroplasty implant for first
metatarsophalangeal joint for use in the treatment
of patients with degenerative and post-traumatic
arthritis in the first metatarsal joint in the presence
of good bone stock along with the following clinical
conditions; hallux valgus or hallux limitus, hallux |
{1}------------------------------------------------
rigidus, and an unstable or painful metatarsal/phalangeal (MTP) joint. The device is a single use implant intended to be used with bone cement.
Substantial Equivalence Information:
The intended use, materials, and application of the Proposed device are substantially equivalent to those of the predicate devices. In determining substantial equivalence. STD Manufacturing's device. CAP™ Great Toe Resurfacing Hemi-arthroplasty implant, has been compared with the following legally marketed device to which the submitter claims equivalence.
- Implant, H.P. condylar, Dow Corning Wright (K781870) .
- � Swanson Titanium Great Toe Implant, Dow Corning Wright (K864492)
- . K2 Hemi-Toe Implant System, Kinetikos Medical, Inc. (K023770)
- Futura Biomedical Metal Hemi Toe Implant, Futura Biomedical((K971047) .
- . Townley Great Toe Joint, Biopro, Inc.(K911378)
## Device Description and Implantation Summary
The CAP™ Great Toe Resurfacinq Hemi-arthroplasty implant is a cobalt chrome alloy, 2-piece implant to supplement first metatarsal phalangeal joint arthroplasty. The implant is designed to provide a smooth surface for the first metatarsophalangeal joint as a the treatment of patients with degenerative and post-traumatic arthritis in the first metatarsal joint in the presence of good bone stock along with the following clinical conditions; hallux valqus or hallux limitus, hallux rigidus, and an unstable or painful metatarsal/phalangeal (MTP) joint. The device is a single use implant intended to be used with bone cement.
The CAP™ Great Toe Resurfacing Hemi-arthroplasty implant consists of two components, a taper post component and an articular component, that mate together via a taper interlock to provide stable and immobile fixation of the implant and stress bearing contact at the bone/prosthetic interface.
The first implant component is a Taper Post manufactured of a Ti-6AI-4V ELI alloy per ASTM F136. The Taper Post has a tapering distal tip, a full-length cannulation, and a proximal female taper bore.
The second implant is an articular component manufactured of a Cobalt-Chromium-Molybdenum alloy per ASTM F799 and ASTM F1537. The articular component has a bone contact surface that is coated with a CP Titanium coating
{2}------------------------------------------------
K031859
page 2 of 6
and a polished articular bearing surface. For greater detail, refer to section 8.2 to view engineering drawings illustrating the various components.
Utilizing the drill guide provided within the CAP™ Great Toe Resurfacing Hemiarthroplasty implant instrumentation set, a surgeon is able to define a working axis that is normal to the articular cartilage surface at the site of the defect. After drilling a pilot hole, theTaper Post is screwed into place using the trial cap to ensure that the surface of the articular component will be tangent and congruent to the existing cartilage surface when seated. Using the contact probe instrument to the explant diameter, offset measurements are taken to define the topography of the patients surrounding articular surface by revolving the probe around a centering shaft coaxial to the working axis of the Taper Post. With these offset measurements, the surgeon is able to select the articular component (sized to match great toe metatarsal head) that will allow it to seat flush to the surrounding articular surface. Offset increments in .5mm sizes will allow for an optimal fit to the existing articular surface.
A reamer, which matches the articular component internal geometry is used to prepare the site for the prosthetic to be implanted. This allows for a precise fit of the implant to the prepared site and minimizes bone resection, so as to provide minimal impact to any future arthroplasty procedure. The articular component is then impacted to seat the taper interlock between the two components.
The prosthetic is intended to provide an effective means for treatment of patients with degenerative and post-traumatic arthritis, hallux valgus, hallux rigidus, hallux limitus, and/or an unstable or painful metatarsal/phalangeal (MTP) joint.
The device has been designed to offer a number of clinical benefits to the user and patient. The device is technically easy to implant, and offers the surgeon a high degree of precision and flexibility in sizing and fitting the articular component to the existing anatomy. A reduction in bone and articular cartilage resection is also offered over the predicate devices, providing a more physiologically normal joint in terms of load and impact distribution.
### Non-clinical Testing conducted to determine substantial equivalence with the predicate devices
Mechanical test protocol has been completed using the proposed device including testing of the taper post component and the articular component per the guidelines established in CDRH Guidance Document for Testing Non-Articulating, Mechanically Locked, Modular Implant Components and ASTM F 1814 "Standard Guide for Evaluating Modular Hip and Knee Joint Components".
{3}------------------------------------------------
K031859
page 4 of 6
The following non-clinical tests were conducted to assess the device performance:
- Axial Assembly and Disassembly .
- Rigidity Characterization �
- Cyclic Fatigue Failure, Disassembly �
- Fretting, Fretting/ Corrosion (ASTM F897) .
- Resistance to Torque of Head Fixation" (ISO 7206-9) .
Final results from these tests demonstrate that the devices meet established acceptance criteria in accordance with the identified industry standards.
Testing to document the required information for the vacuum plasma spray applied surface coating has been previously performed per guidelines established in CDRH Guidance Document for Testing Orthopedic Implants with Modified Metallic Surfaces Apposing Bone or Cement. This documentation exists in the Bio-Coat Master Device File MAF-1085 of which Arthrosurface has been qiven authorization to reference in support of this 510(k) submission.
{4}------------------------------------------------
t) Premarket Notification
™ Great Toe Resurfacing Hemi-arthroplasty Imp
edicate Devic ownley Great
mplant ticular Surfac o bone ceme lone contacti
urface obalt Chrom obalt Chrom Biopro, In <911378 Press fi edicate Device one Cement -tanium plasma Press fit – for gr
blasted tura Biomedi Metal Hemi To
mplant ticular Surfac Bone contact
surface obalt Chron balt Chror <97104 ne contacting sur oposed Device and Predicate De Predicate Device 3
K2 Hemi-Toe Impla
System netikos Medical redicate Device ticular Surfac balt Chrom o cemer 02377 itanium Press fit edicate Device 2 ow Corning Wrig ticular Surfaceobalt Chrome All
Titanium vanson Titani
eat Toe Impla one contactii
urface o cemer 364492 itaniun ress fit Equivalence Comparative Summary
Proposed Device: v Corning Wrig rticular Surface
Ilicone one contactin
urface - Silico 781870 Press fit P™ Great Toe
Surfacing Hemi
Troplasty impla posterials and and september 1990
Station and Comments and Comments of the Stations of the Station
Storial Corporation of Constitution of Constitution of Constitution of C one contacting
urface- Titaniu ticular surfac
obalt Chrome rthrosurfac lloy BD bstantial oduct Name anufacture Mechanica
Fixation Numbe Materia
nfidential Informat
sed (11-12-03) Page
0 1
esection of
ticular surface
section of articleface and bone
tesection of articulurface and bone
esection of
ticular surface ar
Resection of articular surfac
and bone
Resection of
articular surfac
and bone
Site
Preparation
one
oone
Jnknowi
it blasted / titaniu
asma coating
nium plasma coa
inknowi
lo coating
tanium plasm
Goating
Coating
res
Single
Stemmed
spray
(es
/es
Yes
res
o- Doubl
{5}------------------------------------------------
K031859
pge 676
End of 510(K) Summary of Safety and Effectiveness
{6}------------------------------------------------
DEPARTMENT OF HEALTH & HUMAN SERVICES
Image /page/6/Picture/1 description: The image shows the logo for the U.S. Department of Health & Human Services. The logo consists of a circular seal with the text "DEPARTMENT OF HEALTH & HUMAN SERVICES - USA" around the perimeter. Inside the circle is a stylized image of a human figure with three wavy lines extending from the figure's head, representing the department's mission to protect and promote the health and well-being of Americans.
Public Health Service
FEB 1 8 20014
Food and Drug Administration 9200 Corporate Boulevard Rockville MD 20850
Mr. Steven Ek Chief Operating Officer Arthrosurface, Inc. 378 Page Street, Unit 6 Stoughton, MA 02072
Re: K031859
Trade/Device Name: CAP™ Great Toe Resurfacing Hemi-arthroplasty Regulation Number: 21 CFR 888.3730 Regulation Name: Toe joint phalangeal (hemi-toe) polymer prosthesis Regulatory Class: Il Product Code: KWD Dated: November 18, 2003 Received: November 20, 2003
Dear Mr. Fk:
We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration.
If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to such additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the Federal Register.
Please be advised that FDA's issuance of a substantial equivalence determination does not mean that IDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Part 801); good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820); and if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR 1000-1050.
{7}------------------------------------------------
#### Page 2 - Mr. Steven Ek
This letter will allow you to begin marketing your device as described in your Section 510(k) premarket notification. The FDA finding of substantial equivalence of your device to a legally marketed predicate device results in a classification for your device and thus, permits your device to proceed to the market.
If you desire specific advice for your device on our labeling regulation (21 CFR Part 801), please contact the Office of Compliance at (301) 594-4639. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21CFR Part 807.97) you may obtain. Other general information on your responsibilities under the Act may be obtained from the Division of Small Manufacturers, International and Consumer Assistance at its toll-free number (800) 638-2041 or (301) 443-6597 or at its Internet address http://www.fda.gov/cdrh/dsma/dsmamain.html
Sincerely yours.
Sincerely yours,
Mark McMillan
Celia M. Witten, Ph.D., M.D. Director Division of General, Restorative and Neurological Devices Office of Device Evaluation Center for Devices and Radiological Health
Enclosure
{8}------------------------------------------------
510(k) Number: K031859
Device Name: CAP™ Great Toe Resurfacing Hemi-arthroplasty
Indications for Use:
Hemi-arthroplasty implant for first metatarsophalangeal joint for use in the treatment of patients with degenerative and post-traumatic arthritis in the first metatarsal joint in the presence of good bone stock along with the following clinical conditions; hallux valgus or hallux limitus, hallux rigidus, and an unstable or painful metatarsal/phalangeal (MTP) joint. The device is a single use implant intended to be used with bone cement.
(PLEASE DO NOT WRITE BELOW THIS LINE - CONTINUE ON ANOTHER PAGE IF NEEDED)
Concurrence of CDRH, Office of Device Evaluation (ODE)
Prescription Use (Per 21 CFR 801.109 Over-The Counter Use
(Optional Format 1-2-96)
Mark N. Melleuson
Division Sign Off
Division of General, Restorative, and Neurological Devices
**510(k) Number** K031854
---
**Source:** [https://fda.innolitics.com/submissions/OR/subpart-d%E2%80%94prosthetic-devices/KWD/K031859](https://fda.innolitics.com/submissions/OR/subpart-d%E2%80%94prosthetic-devices/KWD/K031859)
**Published by [Innolitics](https://innolitics.com)** — a medical-device software consultancy. We help companies design, build, and clear FDA-regulated software and AI/ML devices. If you're preparing [a 510(k)](https://innolitics.com/services/510ks/), [a De Novo](https://innolitics.com/services/regulatory/), [a SaMD](https://innolitics.com/services/end-to-end-samd/), [an AI/ML medical device](https://innolitics.com/services/medical-imaging-ai-development/), or [an FDA regulatory strategy](https://innolitics.com/services/regulatory/), [get in touch](https://innolitics.com/contact).
**Cite:** Innolitics at https://innolitics.com